The Leading Community for Trusted Peptide Research & Insights
Join a vibrant community sharing real peptide experiences, clinical research, and proven protocols. Data-backed, open, and censorship-free.
Liraglutide is a GLP-1 receptor agonist with 97% sequence homology to native GLP-1. FDA-approved as Victoza (diabetes) and Saxenda (weight management). Established efficacy and safety profile with extensive clinical data.
Summary: Activates GLP-1 receptors to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through central mechanisms. Mechanisms (reported/proposed across domains): Appetite & satiety • Central GLP-1 receptor activation in hypothalamus and brainstem, reducing hunger and increasing satiety signals. Metabolic / glucose control • Enhances insulin secretion...
FDA Approved
Dose: 0.6–3.0 mg (titrated) · Route: Subcutaneous (SC) · Frequency: 1× daily · Duration: 56+ weeks
Join a vibrant community sharing real peptide experiences, clinical research, and proven protocols. Data-backed, open, and censorship-free.